Cramer: Apple Is Th...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$13.39 -0.57 | -4.08%
06/01/12 - 04:03 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 20.90 | n.a. | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.00 | 0.94 | 0.98 |
| Price to Sales (TTM) | 8.77 | 4.21 | 1.42 |
| Price to Book (MRQ) | 9.76 | 3.38 | 2.41 |
| Price to Tangible Book (MRQ) | 15.75 | -8.72 | 5.08 |
| Price to Cash Flow (TTM) | 17.50 | 274.70 | 9.80 |
| Price to Free Cash Flow (TTM) | 28.60 | -63.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.00 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 1.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 23.61 | -0.76 |
| Payout Ratio (TTM) | 0.00 | n.a. | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -7.90 | 37.70 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 6.50 | 1.60 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 12.29 | 7.01 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | -100.00 | 225.80 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 225.80 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | 4.51 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.50 | 1.40 | 1.10 |
| Current Ratio (MRQ) | 3.30 | 2.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.76 | 0.90 | 0.82 |
| Total Debt to Equity (MRQ) | 0.76 | 0.91 | 0.96 |
| Interest Coverage (TTM) | 5.70 | 0.70 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 51.70 | 54.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 57.60 | 54.70 | 47.70 |
| EBITD Margin (TTM) | 9.10 | 17.90 | 18.90 |
| EBITD - 5 Yr Avg | -4.29 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 40.00 | -1.60 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -10.20 | -1.20 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.43 | -0.01 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -7.90 | -1.20 | 7.00 |
| Return on Assets (TTM) | 22.20 | -0.40 | 3.10 |
| Return on Assets - 5 Yr Avg | -4.30 | -0.60 | 2.50 |
| Return on Investment (TTM) | 27.10 | -0.60 | 7.90 |
| Return on Investment - 5 Yr Avg | -5.20 | -0.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 2,183,981.00 | 379,608.00 | 449,376.00 |
| Net Income/Employee (TTM) | 937,864.00 | -4,557.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 6.60 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 2.90 | 8.30 |
| Asset Turnover (TTM) | 0.50 | 0.50 | 0.40 |
Portfolios with ELN
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- ProGeorge Soros
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
- ContributorTechnical Setups for the We...
- Contributor10 Health Care Stocks With ...
Latest ELN Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- On Nowruz, Reviewing Drug Stock Picks 03.26.12 | 07:03 am
- Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past 03.19.12 | 07:03 am
- The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results 02.21.12 | 07:02 am
- Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- 7 Relative Strength Stocks for 2012 12.29.11 | 05:12 pm
- 7 Stocks Hitting New 52-Week Highs 12.21.11 | 01:12 pm
- Your Vote Counts: Who is the Worst Biotech CEO of 2011? 12.01.11 | 10:12 am
- Good Biotech Stocks for a Bear Market 08.09.11 | 08:08 am
Press Releases for ELN
- Elan To Present At Jefferies 2012 Global Healthcare Conference - Business Wire 05.28.12 | 08:05 am
- New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine - Business Wire 05.17.12 | 03:05 pm
- Elan Reports First Quarter 2012 Financial Results - Business Wire 04.26.12 | 02:04 am
- Elan Announces Webcast Of First Quarter 2012 Financial Results - Business Wire 04.12.12 | 04:04 pm
- Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding - Business Wire 03.13.12 | 12:03 pm
- Elan Chairman Provides Update On CEO Succession - Business Wire 03.01.12 | 02:03 am
- Elan Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.08.12 | 02:02 am
- Elan To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.01.12 | 04:02 pm
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
Partner Headlines for ELN
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
- Billionaire Soros' Q1 High Conviction Buys In 2 Growth Stocks, Other Buys And Sells - Seeking Alpha 05.18.12 | 08:05 pm
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Elan Misses 1Q EPS, Revenues Rise - Analyst Blog - Zacks 05.01.12 | 09:05 am
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Tuesday's Bio Pharma Watch List - Seeking Alpha 02.28.12 | 08:02 am
- Zacks Sell List Highlights: Expedia, NII Holdings, Elan and Gentex - Press Releases - Zacks 02.17.12 | 09:02 am
- NII HLDGS-CL B (NIHD) - Profit Tracks - Zacks 02.17.12 | 01:02 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am
